Skip to main content
. Author manuscript; available in PMC: 2022 Jul 15.
Published in final edited form as: Leuk Lymphoma. 2021 Aug 26;63(1):74–83. doi: 10.1080/10428194.2021.1971223

Table 2.

Detailed early PET/CT metrics and association with EOT response

Early PET/CT result EOT responder (n=9) EOT non-responder (n=7) P – value
D4 Visual 24
   Response (CR + PR) 14 (58) 4 (50) 4 (57) 1.0
   Non-response (SD + PD) 10 (42) 4 (50) 3 (43)
D4 ΔSUVmax 23
   >50% 10 (43) 5 (71) 2 (29) 0.29
   ≤50% 13 (57) 2 (29) 5 (71)
D4 ΔSUVmax, median (range) 45 (−76 – 89)* 57 37 0.37
D21 Visual 22
   Response (CR + PR) 7 (32) 3 (38) 2 (33) 1.0
   Non-response (SD + PD) 15 (68) 5 (62) 4 (67)
D21 ΔSUVmax 21
   >50% 5 (24) 3 (43) 1 (17) 0.56
   ≤50% 16 (76) 4 (57) 5 (83)
D21 ΔSUVmax, median (range) 26 (−140 – 89)* 42 29 0.94
Response on D4 & D21 23
   Y 6 (26) 3 (38) 1 (17) 0.58
   N 17 (74) 5 (62) 5 (83)
ΔSUVmax >50% on D4 & D21 22
   Y 4 (18) 3 (43) 0 (0) 0.19
   N 18 (82) 4 (57) 6 (100)
*

positive number represents decrease in SUVmax

Excludes patients who did have early PET/CTs performed but were missing EOT PET/CT evaluation

PET/CT, positron emission tomography/computed tomography; EOT, end-of-treatment; D4, day 4; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; SUVmax, maximum standardized uptake value; D21, day 21